Key clinical point: A once-daily oral drug safely cut respiratory tract infections.
Major finding: During 16 weeks of treatment, the incidence of viral respiratory tract infections was 30.6% lower compared with placebo.
Study details: A phase 2 multicenter, placebo-controlled study of 952 subjects, including 356 randomized to the best-performing dosage.
Disclosures: Dr. Mannick is a cofounder and chief medical officer of resTORbio, the company developing RTB101.
REPORTING FROM IDWEEK 2019